Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
18 Years
N/A
Both
Non Small Cell Lung Cancer
Trial Information
Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
In this study, the patient will be randomized in group 1(experimental arm): docetaxel :75
mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16 and group 2 (control
arm): docetaxel :75 mg/m² IV day 1 every 3 weeks.
Assessment during treatment: Physical examination, ECG,: every 3 weeks, laboratory tests:
weekly, every 3 weeks pulmonary X-ray .The CT scans:. Measurable targets are assessed by
RECIST compared to the beginning of treatment: at 6 weeks (day 42 EVA 2), 12 weeks (D84 EVA
3), 15 weeks (D105 EVA 4: Evaluation of the SSP) and then every 6 weeks until progression.
Quality of life will be assessed Day 42 then every 6 weeks during chemotherapy, Tolerability
will be assessed at each visit based on CTC v4.0 criteria.
Inclusion Criteria:
- Histologically proven NSCLC (
- Mutational status of EGFR : wild type or unknown
- Stage IV disease with cytologic or histologic documentation in patients with a single
easily accessible metastasis or metastatic relapses in a non irradiated region from a
primary tumor treated with surgery or radiotherapy (with cytologic or histologic
documentation of relapse)
- Presence of at least one measurable target lesion (one dimension) in a non irradiated
region (at least 10 mm on spiral computed tomography).
- Age ≥ 18 years
- Performance status 0,1,2 exception : age > 74 years only PS 0 or 1
- Normal hepatic function
- Normal renal function
- Normal calcemia
- Normal haematological function
- Life expectancy > 12 weeks.
- Women of child bearing potential must use effective contraception.
- Men might be surgically sterile or accept to use an effective contraceptive procedure
during and until 6 months after the treatment.
- Written informed consent to participate in the study.
Exclusion Criteria:
- PS > 2, exception : age > 74 years only PS ≥ 2
- Presence of another cancer
- Previous treatment with an anti egfr agent or docetaxel
- QT prolongation (>470 ms)
- Uncontrolled arterial hypertension.
- Concurrent radiotherapy, except for palliative bone irradiation.
- Stroke less than 6 months before study entry.
- Psychiatric or neurological disorders preventing the patient from understanding the
nature of the trial
- Uncontrolled infection.
- Caval syndrome
- Other organic disorders preventing inclusion in the trial
- Malabsorption syndrome
- Allergy to erlotinib or one of its constituents
- Allergy to docetaxel or one of its constituents
- Pregnancy and breast-feeding
- Surgery less than two months before study entry
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression free survival at 15 weeks.
Outcome Time Frame:
at 15 weeks
Safety Issue:
Yes
Principal Investigator
Alain Vergnengre, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University Hospital, Limoges
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
I10004
NCT ID:
NCT01350817
Start Date:
May 2011
Completion Date:
December 2013
Related Keywords:
- Non Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
